A Phase 2a Study of TAS5315 in Patients With Chronic Spontaneous Urticaria

NCT05335499 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

126

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Spontaneous Urticaria

Interventions

DRUG: TAS5315 Dose 1
DRUG: TAS5315 Dose 2
DRUG: TAS5315 Dose 3
DRUG: TAS5315 Dose 4
DRUG: TAS5315 Dose 5
DRUG: Placebo

Sponsor

Taiho Pharmaceutical Co., Ltd.